Last A$0.27 AUD
Change Today 0.00 / 0.00%
Volume 0.0
VLA On Other Exchanges
As of 12:40 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

viralytics ltd (VLA) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/1/13 - A$0.40
52 Week Low
05/6/14 - A$0.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VIRALYTICS LTD (VLA)

Related News

No related news articles were found.

viralytics ltd (VLA) Related Businessweek News

No Related Businessweek News Found

viralytics ltd (VLA) Details

Viralytics Limited, a biotechnology company, develops oncolytic immunotherapy treatments for a range of cancers in Australia. It offers CAVATAK, a lead product that is in phase II clinical trial for the treatment of late stage melanoma, prostate, lung, and bladder cancer, as well as in phase ½ multi-dose intravenous clinical trial for late-stage melanoma, non-small cell lung, metastatic bladder, and castrate-resistant prostate cancer. The company is also conducting various preclinical studies on CAVATAK for the treatment of breast, multiple myeloma, pancreatic, and malignant glioma cancer, as well as for acute myeloid leukemia and chronic lymphocytic leukemia. In addition, it is developing EVATAK, which is in pre-clinical studies for treating ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia.

3 Employees
Last Reported Date: 08/26/14

viralytics ltd (VLA) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$429.0K
Chief Financial Officer
Total Annual Compensation: A$149.5K
Chief Scientific Officer
Total Annual Compensation: A$195.7K
Compensation as of Fiscal Year 2014.

viralytics ltd (VLA) Key Developments

Viralytics Limited Announces Board Appointments

Viralytics Limited appointed former CSL executive Peter Turvey to its board of directors along with CEO Dr. Malcolm McColl. Mr. Turvey has been appointed non-executive director. Dr. McColl's election to the board and elevation to the position of Managing Director & CEO comes after a very successful first 18 months as CEO of Viralytics.

Viralytics Limited Reports Audited Consolidated Earnings Results for the Full Year Ended June 30, 2014

Viralytics Limited reported audited consolidated earnings results for the full year ended June 30, 2014. For the year, total revenue was AUD 2,803,892 against AUD 2,755,815 a year ago. Loss from ordinary activities before income tax was AUD 5,528,629 against AUD 4,129,729 a year ago. Total loss, net of tax was AUD 5,528,629 or 4.6 cents per basic and diluted share against AUD 4,129,729 or 5.1 cents per basic and diluted share a year ago. Net cash used in operating activities was AUD 5,486,038 against AUD 3,934,332 a year ago. Purchase of equipment was AUD 7,876 against AUD 40,383 a year ago.

Viralytics Limited Presents at 2014 Bioshares Biotech Summit, Jul-19-2014 08:50 AM

Viralytics Limited Presents at 2014 Bioshares Biotech Summit, Jul-19-2014 08:50 AM. Venue: Rydges Lakeland Resort, Queenstown, New Zealand. Speakers: Malcolm L. McColl, Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VLA:AU A$0.27 AUD 0.00

VLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VLA.
View Industry Companies

Industry Analysis


Industry Average

Valuation VLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.5x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIRALYTICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at